Terveystalo Oyj (0RV1)
London Exchange · UK · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 5.940 |
|---|---|
| 52-week range | 5.940 – 10.380 |
| Return, 1 month / 3 months | −19.2% / −11.9% |
| Return, 1 year / 3 years | −30.1% / −9.5% |
| Trend | Below its 200-day average |
| RSI (14) | 13 |
| Volatility (1 year) | 23.7% |
| Worst drawdown (1 year) | -37.6% |
| Average daily value traded | 0.27M EUR |
| Dividend yield | 10.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Terveystalo Oyj is a private healthcare services company based in Finland. It provides occupational health services to employers, along with primary care, specialist medical care, diagnostics and dental services to private customers and public sector clients. Care is delivered through a network of clinics and digital services across the country, and the company also offers wellbeing and rehabilitation services. Its customers include companies, insurers, municipalities and individual patients.
The shares are listed on the London Exchange in UK under the code 0RV1, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Terveystalo Oyj (0RV1) trades on the London Exchange in UK. It last closed at EUR 5.940 on 23 October 2026.
Its price-based Market X-Ray is 39 out of 100 (a weak price profile), ranking 2,681 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 30.1% and over the last three months it fell 11.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 18 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -23.9% | ||
| From 52-week high | -42.4% | ||
| Momentum | 22 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -11.9% | ||
| 6-month return | -24.8% | ||
| 12-month return, skipping the last month | -13.5% | ||
| Stability (higher is calmer) | 57 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 23.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -37.6% | ||
| Liquidity | 40 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.27M EUR | ||
| Zero-volume days | 10.0% | ||
| Income | 90 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 10.8% | ||
| Years with dividends | 6 |
Strengths
- Income: Dividend is high and has been paid regularly.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −16.1% |
|---|---|
| 1 month | −19.2% |
| 3 months | −11.9% |
| 6 months | −24.8% |
| 1 year | −30.1% |
| 3 years | −9.5% |
| 5 years | −34.4% |
Signals
| 50-day / 200-day average | 7.209 / 7.801 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.155 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 7 Oct 2026 | EUR 0.3200 |
| 25 Mar 2026 | EUR 0.3200 |
| 7 Oct 2025 | EUR 0.2400 |
| 9 Apr 2025 | EUR 0.2400 |
| 8 Oct 2024 | EUR 0.1500 |
| 27 Mar 2024 | EUR 0.1500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.